Market closed
FibroBiologics/$FBLG
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About FibroBiologics
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
Ticker
$FBLG
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
10
Website
FibroBiologics Metrics
BasicAdvanced
$84M
Market cap
-
P/E ratio
-$0.57
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$84M
52-week high
$55.00
52-week low
$1.08
Average daily volume
191K
Financial strength
Current ratio
1.228
Quick ratio
1.172
Long term debt to equity
38.546
Total debt to equity
57.07
Interest coverage (TTM)
-833.67%
Management effectiveness
Return on assets (TTM)
-65.77%
Return on equity (TTM)
-267.86%
Valuation
Price to book
29.87
Price to tangible book (TTM)
29.87
Price to free cash flow (TTM)
-7.196
Growth
Earnings per share change (TTM)
47.12%
What the Analysts think about FibroBiologics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for FibroBiologics stock.
FibroBiologics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
FibroBiologics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
FibroBiologics News
AllArticlesVideos
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
GlobeNewsWire·4 days ago
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
GlobeNewsWire·1 week ago
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for FibroBiologics stock?
FibroBiologics (FBLG) has a market cap of $84M as of November 23, 2024.
What is the P/E ratio for FibroBiologics stock?
The price to earnings (P/E) ratio for FibroBiologics (FBLG) stock is 0 as of November 23, 2024.
Does FibroBiologics stock pay dividends?
No, FibroBiologics (FBLG) stock does not pay dividends to its shareholders as of November 23, 2024.
When is the next FibroBiologics dividend payment date?
FibroBiologics (FBLG) stock does not pay dividends to its shareholders.
What is the beta indicator for FibroBiologics?
FibroBiologics (FBLG) does not currently have a Beta indicator.